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Pro- and anti-inflammatory cytokines and their signaling pathways play key roles in protection from and
pathogenesis of mycobacterial infection, and their balance and dynamic changes may control or predict clinical
outcome. Peripheral blood cells’ capacity to produce proinflammatory (tumor necrosis factor alpha [TNF-],
interleukin-12/23p40 [IL-12/23p40], and gamma interferon [IFN-]) and anti-inflammatory (IL-10) cytokines in
response to Mycobacterium tuberculosis or unrelated stimuli (lipopolysaccharide, phytohemagglutinin) was studied
in 93 pulmonary tuberculosis (TB) patients and 127 healthy controls from Indonesia. Their cells’ ability to respond
to IFN- was examined to investigate whether M. tuberculosis infection can also inhibit IFN- receptor (IFN-R)
signaling. Although there was interindividual variability in the observed responses, the overall results revealed that
M. tuberculosis-induced TNF- and IFN- levels showed opposite trends. Whereas TNF- production was higher in
active-TB patients than in controls, IFN- production was strongly depressed during active TB, correlated inversely
with TB disease severity, and increased during therapy. By contrast, mitogen-induced IFN- production, although
lower in patients than in controls, did not change during treatment, suggesting an M. tuberculosis-specific and
reversible component in the depression of IFN-. Depressed IFN- production was not due to decreased IL-12/IL-23
production. Importantly, IFN--inducible responses were also significantly depressed during active TB and nor-
malized during treatment, revealing disease activity-related and reversible impairment in IFN-R signaling in TB.
Finally, IFN-/IL-10 ratios significantly correlated with TB cure. Taken together, these results show that M.
tuberculosis-specific stimulation of IFN- (but not TNF-) production and IFN-R signaling are significantly
depressed in active TB, correlate with TB disease severity and activity, and normalize during microbiological TB
cure. The depression of both IFN- production and IFN-R signalingmay synergize in contributing to defective host
control in active TB.
Although one-third of the world’s population is thought to
be latently infected with Mycobacterium tuberculosis (15), it
remains largely unclear why in only 5 to 10% of individuals’
infections will progress to active tuberculosis (TB) during their
lifetimes (53). Given the impact of mycobacterial exposure and
its immunoregulatory consequences for host immunity, it is
important to study the integrity and regulation of immune
responses and their downstream signaling pathways in areas
where TB is endemic since most individuals will be exposed to
tuberculous and environmental mycobacteria.
The control of mycobacterial infection is dependent on cell-
mediated immunity (CMI), involving activated macrophages, T
cells, and type 1 cytokines (23, 40). Upon triggering of innate
microbial pattern recognition receptors, such as Toll-like re-
ceptors (TLRs) (22), mannose receptors (19, 30), type C lectins
like DC-SIGN (25, 48), and NOD/NACHT receptors (21),
phagocytes are activated to produce proinflammatory cyto-
kines, including tumor necrosis factor alpha (TNF-), inter-
leukin-1 (IL-1), and IL-12, and particularly in the case of
DC-SIGN, also anti-inflammatory cytokines, including IL-10
and transforming growth factor beta (TGF-) (22). TNF- is a
monocyte-activating cytokine which stimulates antimycobacte-
rial activity and helps to maintain the integrity of the tubercu-
lous granulomas in which M. tuberculosis is contained (52).
IL-12 (p40/p35) links innate and adaptive immunity; drives T
cells and NK cells to produce Th1 proinflammatory cytokines,
including IFN- and TNF-; and regulates IL-17 production
(28, 40, 43). In synergy with TNF-, IFN- activates infected
macrophages to eliminate intracellular pathogens as a major
effector mechanism of CMI. IL-10 is generally considered to be
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an anti-inflammatory cytokine and is produced by alternatively
activated macrophages (57), DC subsets, and Th2, Th3, and
subsets of T-regulatory cells (8, 37). IL-10 down-regulates
IL-12 production, decreases IFN- production, and regulates
antigen presentation (5, 32). Genetic deficiencies in the type 1
cytokine network (IL-12/IL-23/IL-12R/IL-23R/IFN-/IFN-R/
STAT1) have been found in patients suffering from severe
infections due to otherwise poorly pathogenic mycobacteria
and salmonellae (reviewed in references 41 and 55). These
unfortunate experiments of nature lead to a failure to produce
or to respond to IFN- and underline the crucial role of this
network in optimal host defense against mycobacterial patho-
gens.
There is ample evidence suggesting strong immunoregula-
tion and temporary immune suppression in active TB. It is well
known that the capacity of active-TB patients to produce
IFN- as determined in blood stimulation assays is depressed
(18, 27, 29, 39, 47, 51). Although there is evidence suggesting
that sequestration of reactive cells into active lesions may con-
tribute to the lower responses in the peripheral compartment,
it is thought that active suppressive mechanisms contribute to
these depressed responses. Indeed, TB patients have enhanced
levels of IL-10 and TGF- (17, 26, 50). However, it is unknown
whether this impairment in IFN- production during active TB
is antigen specific or rather a generalized phenomenon. More-
over, besides the depressed IFN- production, in vitro exper-
iments have suggested that M. tuberculosis or components
thereof are able to down-regulate IFN- receptor (IFN-R)
signaling. This could further undermine the impact of the al-
ready diminished levels of IFN- on immune activation. As an
example, M. tuberculosis 19-kDa lipoprotein can inhibit IFN-
-induced regulation of various genes via TLR/MyD88-depen-
dent and TLR/MyD88-independent mechanisms, impairing
binding of Stat1 to downstream transcription factors (24, 42,
49). Most of these studies, however, have been carried out in in
vitro model systems, and it is has not been well studied whether
this effect also impacts on the human host defense against M.
tuberculosis in infected individuals, including active-TB pa-
tients.
We therefore decided to study possible defects—acquired or
inherent—in the type 1 cytokine network in TB in a compre-
hensive fashion in a setting where TB is highly endemic. Indo-
nesia currently ranks third among the world’s countries in TB
prevalence (59). We evaluated the capacity of TB patients’
peripheral blood cells before, during, and after treatment to
produce pro- versus anti-inflammatory cytokines (TNF-, IL-
12/23p40, IFN-, IL-10) in response to M. tuberculosis or un-
related stimuli (lipopolysaccharide [LPS], phytohemagglutinin
[PHA]). Simultaneously, we studied their ability to respond to
IFN- in view of the cited evidence that M. tuberculosis infec-
tion inhibits IFN-R signaling in vitro. Cytokine responses and
profiles were analyzed cross-sectionally in relation to clinical
severity and longitudinally in relation to treatment outcome.
MATERIALS AND METHODS
Study subjects. In a case-control study, 120 newly diagnosed active pulmonary
TB patients (ages, 15 to 60 years) were recruited from January 2002 to December
2004 at Perkumpulan Pemberantasan Tuberkulosis Indonesia, an outpatient TB
clinic in central Jakarta. TB diagnosis was performed according to World Health
Organization criteria, on the basis of the clinical presentation and a chest X-ray
radiograph (CXR), and was confirmed by microscopic detection of acid-fast
bacilli in Ziehl-Nielsen-stained sputum smears and positive culture of M. tuber-
culosis. Human immunodeficiency virus (HIV)-seropositive patients (3.3%), di-
abetes mellitus (DM)-affected patients (10.7%), patients with heart diseases
(1.7%), and patients with incomplete data records (5%) were excluded. TB
patients entering the study (n  93) were classified as having mild-to-moderate
TB (n  41) or advanced TB (n  52) on the basis of the extent of lesions on
CXR as described elsewhere (20). Free anti-TB drug treatment was provided to
all patients and consisted of a standard regimen of isoniazid, rifampin, pyrazin-
amide, and ethambutol (2HRZE/4H3R3) according to the national TB program.
Treatment was supervised once weekly by a directly observed treatment pro-
gram. A subgroup of patients (n  53) was followed longitudinally. This group
was selected according to exactly the same criteria as above.
In the same period, 144 healthy individuals matched for sex and age (10%)
and living within the same rukun tetangga, the smallest residential unit in Jakarta
(consisting of 15 to 30 households), were included as control subjects. Controls
were interviewed by using the same standardized questionnaire and subjected to
the same physical examination, blood testing, and CXR scheme as the TB
patients. Controls with signs, symptoms, and CXR results suggestive of active TB
(2.1%), a history of prior anti-TB treatment (1.4%), DM (1.4%), or incomplete
data entry (6.9%) were excluded. HIV status was not tested in the control group.
Indonesia is classified as a country with a low HIV prevalence of 0.1% in 2003
(33, 59). Included controls (n  127) had either a normal CXR (n  110) or a
CXR with minimal pulmonary calcifications (n  17) suggestive of postprimary
TB infection. The latter were not excluded because they had never taken anti-TB
drugs.
This study was approved by the Ethical Committee of the Faculty of Medicine,
University of Indonesia, Jakarta, and by the Eijkman Institute Research Ethics
Committee, Jakarta, and written informed consent was voluntarily signed by all
patients and control subjects.
Ex vivo stimulation of whole blood and isolated mononuclear cells. Ex vivo
cytokine production was examined in patients before initiation of TB treatment.
In addition, a group of patients was examined again after 2 and 6 months of TB
treatment, respectively. Healthy controls were examined only at the moment of
enrollment in the study. To assess cytokine responses, 200 l of heparinized
venous blood was diluted (1:10) in Iscove’s modified Dulbecco’s medium (Gibco
Invitrogen) and incubated in 96-well round-bottom plates in triplicate in the
presence of 10 g/ml M. tuberculosis H37Rv sonicate (heat killed and ultrasoni-
cated; gift from D. van Soolingen, Rijksinstituut voor Volksgezondheid en Mi-
lieu, Bilthoven, The Netherlands) or 100 ng/ml LPS (Escherichia coli serotype
O55:B5; Sigma-Aldrich Chemie BV) in the presence or absence of 50 or 500
U/ml IFN- (Immukine; Boehringer Ingelheim). Cultures were incubated at
37°C in a fully humidified incubator (5% CO2), and supernatants were harvested
after 4 h to measure TNF- production and after 24 h to measure IL-12/23p40
and IL-10 production.
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized
venous blood by Ficoll-Hypaque (Pharmacia Biotech) density gradient centrifu-
gation. Freshly isolated PBMCs (1.5  105 per well) were incubated in 96-well
round-bottom plates in triplicate for 6 days in the presence of 2 or 10 g/ml M.
tuberculosis sonicate or 4 g/ml PHA (Murex Biotech Ltd.). Cultures were
incubated at 37°C in a fully humidified incubator (5% CO2). Supernatants were
harvested after 6 days and stored at 	20°C until IFN- enzyme-linked immu-
nosorbent assay measurement.
Cytokine measurement. TNF-, IL-12/23p40, IL-10 (Biosource), and IFN-
(U-CyTech) were measured with a standard enzyme-linked immunosorbent as-
say according to the manufacturer’s protocol. To determine precise concentra-
tions, serial dilutions of the test samples’ supernatants were always tested (in
duplicate). The detection limits of the assays were 8 pg/ml for TNF-, IL-12/
23p40, and IL-10 and 15 pg/ml for IFN-. The cutoff value used was 30 pg/ml,
corresponding to three standard deviations above the mean values found in the
standard negative control cultures. Detectable values in unstimulated cultures
from an individual were subtracted from the values of the stimulated cultures
from the same individual.
Statistical analyses. The t test (independent or paired) was used to compare
means of clinical laboratory parameters (Table 1). The Kruskal-Wallis nonpara-
metric test was used to test differences between responses among three or more
groups, whereas the Mann-Whitney U test was used to test two groups. In the
follow-up study, Wilcoxon signed-rank tests were used to compare median values
obtained before, during, and at the end of TB therapy. All statistical analyses
were two sided, and a P value of 0.05 was considered statistically significant.
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RESULTS
Clinical severity of TB in patients. The clinical severity of
pulmonary TB in patients was determined on the basis of the
extent of lesions on CXR and classified into mild-to-moderate
TB (n  41) and advanced TB (n  52) and is compared to
that of healthy control subjects (n  127) in Table 1. Tuber-
culin skin tests were not performed in our study. BCG status
was determined by the presence of a BCG scar. Interestingly,
the mild-to-moderate TB group had significantly more BCG
scars (48.8%) than the advanced-TB group (26.9%, P 
 0.05).
There was no such difference between the mild-to-moderate
TB patient group and the healthy control group (45.7%). More
than 95% of the active-TB patients had persistent coughing as
the main complaint. The duration of this symptom was shorter
in mild-to-moderate TB (17.8  3.2 weeks) than in advanced
TB (23.7  3.0 weeks), although this difference was not statis-
tically significant. The body mass index (BMI) in advanced-TB
patients was significantly lower than that of patients with mild-
to-moderate TB (16.9  0.3 versus 18.6  0.4, P 
 0.05) and
control subjects (22.4  0.3, P 
 0.05). Anemia (corrected by
gender, the hemoglobin [Hb] level for males was 13 g/dl and
that for females was 12 g/dl) was more prominent in ad-
vanced TB (86.0%; mean Hb, 11.4 g/dl) than in mild-to-mod-
erate TB (57.5%; mean Hb, 12.2 g/dl). Laboratory parameters,
such as the erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP) level, white blood cell indices (WBC), and gran-
ulocyte numbers were all significantly different between TB
patients and controls. They were also significantly higher in
advanced-TB than in mild-to-moderate TB patients, in agree-
ment with the CXR results.
After the completion of 6 months of anti-TB therapy, 86
patients were cured on the basis of conversion to negative
sputum microscopy results. They also showed improved clinical
appearance and reduction of the lesion area in the CXR.
Treated TB patients had significant weight gain (19.8 kg/m2;
P 
 0.01) and a decreased ESR (21.5  3.1 mm/h; P 
 0.01),
while CRP levels decreased to normal (10 mg/liter; P 

0.01). Also, all other blood parameters approached normal
values in treated TB patients (Table 1). Seven TB patients
showed persistently positive sputum microscopy results. None
of them were infected with multidrug-resistant M. tuberculosis
strains. Only one of these seven patients still showed a high
CRP level (31 mg/liter) but had a normalized BMI (20.8 kg/m2)
at month 6. Two patients had normalized CRP levels with
normalized BMIs, while four other patients had normalized
CRP levels with BMIs still under 18.5 kg/m2. Those four pa-
tients, however, had gained significant weight compared to
when they were in the active-TB phase.
Clinical TB severity is often classified on the basis of chest
radiography results, ranging from infiltration in a limited upper
lung segment to extensive bilateral lung involvement with tis-
sue destruction and cavitation (56). Since CXR readings are
subject to intra- and interobserver variations, we compared our
CXR-based classification of mild-to-moderate TB versus ad-
vanced TB with other clinical presentations and laboratory
parameters. CXR severity classifications matched well with
clinical symptoms, including wasting, a prominent feature of
TB (56), with the extent of lymphopenia associated with ane-
mia (38), and with increases in white blood cell numbers with
high numbers of granulocytes.
Proinflammatory (TNF-, IL-12/23p40) and anti-inflamma-
tory (IL-10) cytokine production in response to M. tuberculosis
or LPS. Cytokine responses were analyzed cross-sectionally as
well as longitudinally. In the cross-sectional analysis, M. tuber-
culosis-induced (Fig. 1a) or LPS-induced (data not shown)
TNF- production was highest in untreated TB patients, in-
termediate during therapy, and lowest at the end of TB therapy
(medians, 143, 122, and 93 pg/ml, respectively), closely ap-
proaching the values measured in control subjects (median, 83
pg/ml). TNF- production levels in untreated TB patients were
TABLE 1. Clinical characteristics of pulmonary TB patients before and at the end of TB therapy compared to those of control subjectsa
Parameter
Pulmonary TB patients
Controls
(n  127)
Before TB therapy
End of TB therapy
(n  86)Mild-to-moderate
TB (n  41)
Advanced
TB (n  52)
Median age (range), yr 29 (17–52) 30 (18–55) 30 (17–58)
No. (%) of males 23 (56.1) 30 (57.7) 70 (55.1)
No. (%) of individuals with BCG scar 20 (48.8) 14 (26.9)b 58 (45.7)
Mean symptom duration  SE (wk) 17.8  3.2 23.7  3.0
Mean BMI  SE (kg/m2) 18.6  0.4 16.9  0.3b 19.8  0.3c,e 22.4  0.3d
Mean ESR  SE (mm/h) 71.8  5.0 93.7  4.2b 22.4  3.2c,f 17.2  1.3d
Mean CRP level  SE (mg/liter) 45.5  5.5 83.0  5.7b 8.0  1.1c,e 6.0  0.7d
Mean Hb level  SE (g/dl) 12.2  0.2 11.4  0.2b 13.7  0.3c,g 14.5  0.1d
Mean WBC  SE (103/l) 10.9  0.6 13.2  0.6b 7.8  0.5c,g 8.3  0.2d
Mean lymphocyte count  SE (103/l) 2.4  0.1 2.4  0.1 2.6  0.1c,g 2.9  0.1d
Mean granulocyte count  SE (103/l) 7.8  0.5 10.0  0.6b 4.7  0.4c,g 4.9  0.1d
a Clinical severity of pulmonary TB in patients was determined on the basis of the extent of lesions on CXR and classified into mild-to-moderate TB and advanced
TB. Eighty-six patients were cured on the basis of conversion to negative sputum microscopy examinations, improved clinical appearance, and a reduction of the lesion
area in the CXR. All blood parameters in treated TB patients approached normal values.
b Statistically significant difference (P 
 0.05) between mild-to-moderate and advanced pulmonary TB before therapy (t test).
c Statistically significant difference (P 
 0.05) between pulmonary TB patients before and at the end of therapy (paired t test).
d Statistically significant difference (P 
 0.05) between all pulmonary TB patients before therapy and control subjects (t test).
e Value measured in 81 patients.
f Value measured in 39 patients.
g Value measured in 21 patients.
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significantly increased compared to those of controls (P 
0.007), correlating with TB disease-related inflammation. In-
duced TNF- levels were significantly higher following stimu-
lation with LPS compared to M. tuberculosis sonicate (P 

0.001), but the same decrease in production during treatment
was noticeable (data not shown).
A smaller set of patients (mild-to-moderate TB, n  26;
advanced TB, n  27) could be followed-up in a longitudinal-
observation study. No significant differences in TNF- produc-
tion were observed between the mild-to-moderate TB (Fig. 1b)
and advanced-TB (Fig. 1c) groups before, during, and at the
end of therapy, although group sizes were limited. Taken to-
gether, these data suggest that TNF- production is enhanced
in active TB, normalizes during curative treatment, and corre-
lates with TB disease activity rather than disease severity.
In contrast to TNF-, IL-12/23p40 production tended to be
slightly increased after 2 months of TB therapy but was de-
creased at the end of anti-TB therapy in the cross-sectional
analysis. This trend was most evident in the longitudinal study
in the mild-to-moderate TB patients, compared to the ad-
vanced-TB patients, who showed a gradual decline in IL-12/
23p40 production during TB therapy (Fig. 2). However, these
trends failed to reach statistical significance (not shown). Like
TNF-, IL-12/23p40 production levels were significantly higher
upon stimulation with LPS compared to M. tuberculosis (P 

0.01), although the observed trends were the same (data not
shown).
IL-10 production in response to M. tuberculosis sonicate was
below the detection limit of our assay in most patients and
controls. This was presumably due to the limited number of
cells present in the assay. In response to LPS, however, IL-10
production was slightly but significantly increased in active
TB (median, 164 pg/ml) and normalized at the end of therapy
(median, 120 pg/ml) compared to that of the control group
(median, 121 pg/ml; P 
 0.03) (Fig. 3). In the longitudinal
study, no significant differences were detectable between
the mild-to-moderate TB and advanced-TB subgroups (not
shown).
IFN- production in response toM. tuberculosis compared to
PHA. PBMC IFN- production was strongly depressed in re-
FIG. 1. (a) M. tuberculosis-induced TNF- production in the cross-
sectional analysis was highest in untreated TB patients, decreased
during therapy, and was lowest at the end of TB therapy, closely
approaching the values measured in control subjects, correlating with
the TB disease-related inflammatory process. A smaller set of patients
was followed up in a longitudinal-observation study. No significant
differences in TNF- production were observed between the mild-to-
moderate TB (b) and advanced-TB (c) groups before, during, and at
the end of the therapy. Each dot in the cross-sectional study represents
one individual. A horizontal bar indicates the median of each group. A
dashed line indicates the lower detection limit of the assay. A statis-
tically significant difference (P 
 0.05) is indicated by the asterisk
(Mann-Whitney U test).
FIG. 2. M. tuberculosis-induced IL-12/23p40 production tended to
be slightly increased after 2 months of TB therapy but decreased at the
end of anti-TB therapy in the cross-sectional analysis. This trend was
most evident in the longitudinal study (see text; not shown). Each dot
in the cross-sectional study represents one individual. A horizontal bar
indicates the median of each group. A dashed line indicates the lower
detection limit of the assay. A statistically significant difference (P 

0.05) is indicated by the asterisk (Mann-Whitney U test).
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sponse to M. tuberculosis in untreated TB but increased during
the course of therapy, approaching values measured in control
subjects at the end of therapy (medians, 49, 463, and 1,353
pg/ml compared to 1,343 pg/ml in controls). Thus, IFN- pro-
duction correlated inversely with TB disease activity (Fig. 4a).
There was a clear dose effect, since levels of IFN- production
were lower in response to 2 g/ml M. tuberculosis sonicate than
in response to 10 g/ml M. tuberculosis sonicate, but the same
trend was observed (data not shown). Exclusion of the 17
controls with CXR suggestive of postprimary M. tuberculosis
infection (n  17; median, 1,604 pg/ml) did not change the
IFN- production results in the control group (n  110; me-
dian, 1,283 pg/ml) compared to TB patients. P values in the
case of the total control group (n  127) or the group from
which the 17 subjects had been excluded (n  110), compared
to the TB group, were as follows: prior to treatment, P
 0.001
in both cases; during treatment, P  0.01 and 0.03; following
completion of therapy, not different, as expected (P  0.5 and
0.3, respectively).
A smaller set of patients (mild-to-moderate TB, n  19; ad-
vanced TB, n  29) could be studied longitudinally. Overall,
IFN- production in response to M. tuberculosis sonicate was
higher in mild-to-moderate TB than in advanced TB at all of the
time points studied (medians: before treatment, 370 versus 
30
pg/ml [P 
 0.01]; during treatment, 963 versus 235 pg/ml [P 
0.02]; end of therapy, 2,154 versus 795 pg/ml [P  0.05], respec-
tively) (Fig. 4b and c). These results show that, in contrast to the
observed changes in TNF-, IL-10, and IL-12/23p40, the de-
creased IFN- production correlates not only with TB disease
activity but also with TB disease severity.
Nonspecific stimulation with the T-cell mitogen PHA, which
assesses the overall capacity of T cells to produce cytokines,
also revealed significantly depressed IFN- production in TB
patients compared to controls (P 
 0.0001). In contrast to the
FIG. 3. LPS-induced IL-10 production of pulmonary TB patients
was slightly but significantly increased in active TB and normalized at
the end of therapy compared to that of the control group. In the
longitudinal study, no significant differences were detectable between
the mild-to-moderate TB and advanced-TB subgroups (see text; not
shown). Each dot in the cross-sectional study represents one individ-
ual. A horizontal bar indicates the median of each group. A dashed
line indicates the lower detection limit of the assay. A statistically
significant difference (P 
 0.05) is indicated by the asterisk (Mann-
Whitney U test).
FIG. 4. (a) M. tuberculosis-induced IFN- production of PBMCs
was strongly suppressed in untreated TB but increased during the
course of therapy, approaching values measured in control subjects at
the end of therapy, correlating inversely with TB disease activity. Over-
all, IFN- production was higher in mild-to-moderate TB patients (b)
than in advanced-TB patients (c) at all of the time points studied,
showing that, in contrast to TNF-, IL-10, and IL-12/23p40, the de-
pression in IFN- production correlates not only with TB disease
activity but also with TB disease severity. Each dot in the cross-sec-
tional study represents one individual. A horizontal bar indicates the
median in each group. A dashed line indicates the lower detection limit
of the assay. Statistically significant differences (P
 0.05) are indicated
by the symbol # between median values before, during, and at the end
of the therapy (Wilcoxon signed-rank test); by the symbol  compared
to control subjects (Mann-Whitney U test); and by the symbol [o]
between mild-to-moderate TB and advanced-TB patients (Mann-
Whitney U test).
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results from M. tuberculosis-specific stimulation, however,
there was no increase in IFN- production during anti-TB
therapy (Fig. 5). There was also no significant difference be-
tween mild-to-moderate TB and advanced TB at the first and
third time points studied, although there were slightly en-
hanced levels in mild-to-moderate TB compared to ad-
vanced-TB cases after two months of therapy (not shown).
Taken together, these results show suppression of IFN- im-
mune responses during active TB disease, with a prominent
antigen-specific component which seems reversible and an an-
tigen nonspecific component which seems more permanent.
IFN- production and clinical severity. The presence of a
BCG scar correlated with protection against advanced TB (Ta-
ble 1). However, IFN- production levels within each of the
patient groups did not correlate with the presence of a BCG
scar. IFN- production also did not correlate with any other
laboratory parameters such as Hb, WBC, or granulocyte num-
bers. Low IFN- production induced by M. tuberculosis (100
pg/ml) during the entire treatment period was found in 4 out of
31 patients. Low responses to M. tuberculosis were also ob-
served in 18 (14%) out of 127 control subjects. Of these, only
one showed calcification in CXR suggestive of postprimary TB.
However, all of these individuals responded well to PHA. Two
advanced-TB patients with a low response to PHA before
treatment showed increased production at the end of therapy.
We also separately analyzed IFN- production in TB pa-
tients in relation to their DM status, since 13 patients had
concomitant DM and DM has a strong relationship with TB in
Indonesia (1). However, no differences were found between
the two groups. In a more recent study that we have carried out
in the same area, also no differences in ex vivo cytokine pro-
duction were found in TB patients with or without DM (J.
Stalenhoef et al., unpublished data).
Integrity of the IFN-R signaling pathway in TB. In order to
assess the integrity of the IFN-R signaling pathway in TB, we
analyzed the ability of patients’ and controls’ cells to respond
to exogenous IFN- by enhancing M. tuberculosis or LPS in-
duction of TNF-. IFN- significantly enhanced M. tuberculo-
sis- and LPS-driven production of TNF- (and IL-12/23p40
[not shown]). In Fig. 6, IFN- responsiveness is expressed as
the ratio of M. tuberculosis plus IFN- to M. tuberculosis only.
During active TB, the ratio of M. tuberculosis plus IFN-- to M.
tuberculosis-induced production of TNF- was decreased sig-
nificantly compared to that of controls but normalized during
the course of therapy (P 
 0.05) to levels comparable to those
of the control group. These data thus may indicate that
IFN-R signaling is compromised during active TB. An alter-
native explanation might be that active-TB patients already
have higher starting levels of TNF- which may be more dif-
ficult to upregulate further. However, we also found impair-
ment of IFN--dependent TNF- upregulation at the lower
stimulatory M. tuberculosis concentrations used, which give rise
to lower primary levels of TNF-, as well as in the case of LPS
stimulation, which gives rise to higher TNF- levels, such that
we favor the first interpretation.
Proinflammatory and anti-inflammatory cytokine ratios.
Since the balance between proinflammatory and anti-inflam-
matory cytokines is important in clinical outcome in several
human diseases, we calculated ratios of TNF- to IL-10 and
IL-12/23p40 to IL-10. TNF-/IL-10 ratios were significantly
increased in TB patients at all time points before, during, and
following completion of therapy compared to those of the
control subjects (P 
 0.05). By contrast, IL-12/23p40/IL-10
ratios were only temporarily increased during anti-TB therapy
FIG. 5. PHA-induced IFN- production of PBMCs was strongly
suppressed in patients with untreated TB compared to that in controls.
In contrast to the results from M. tuberculosis-specific stimulation, no
increased IFN- production during anti-TB therapy was observed.
There was overall no significant difference between mild-to-moderate
TB patients and advanced-TB patients (see text; not shown). Each dot
in the cross-sectional study represents one individual. A horizontal bar
indicates the median in each group. A dashed line indicates the lower
detection limit of the assay. Statistically significant differences (P 

0.05) are indicated by asterisks (Mann-Whitney U test).
FIG. 6. IFN- responsiveness as measured by synergy in TNF-
induction upon stimulation with M. tuberculosis sonicate (ratio of M.
tuberculosis plus IFN- to M. tuberculosis only). IFN- significantly
enhanced M. tuberculosis-driven production of TNF-. IFN- respon-
siveness was decreased significantly in active-TB patients compared to
that of controls and normalized during therapy to levels comparable to
those of the control group. Each dot represents the IFN- response
ratio of one individual. A dashed line indicates a ratio of 1. A hori-
zontal bar indicates the median level of each group. Statistically sig-
nificant differences (P 
 0.05) are indicated by the symbol # between
median values before, during, and at the end of the therapy (Wilcoxon
signed-rank test) and by the symbol  compared to control subjects
(Mann-Whitney U test).
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and decreased at the end of therapy. The ratio of M. tubercu-
losis-specific induced IFN- over IL-10 production showed a
strong increase during the course of therapy and was slightly
increased at the end of therapy compared to that of control
subjects (Fig. 7). Differences were statistically significant at all
times points. A similar result was found for IFN- over TNF-
ratios (not shown). These results strongly suggest a shift to-
ward a proinflammatory host immune phenotype during con-
trol of infection and also suggest that IFN-/IL-10 ratios may
be a useful biomarker signature to assess this (Fig. 7). The
IFN-/IL-10 ratio, in particular, was slightly more sensitive
than IFN-measurements alone; although before therapy both
were significantly differed from those in the control group at a
level of P 
 0.0001, during therapy the IFN-/IL-10 ratio
showed a slightly more pronounced difference compared to
IFN- alone (P  0.004 versus 0.01). As expected, after ther-
apy neither was different from the control group (P  0.2 and
0.5 for IFN-/IL-10 and IFN- alone, respectively). The
slightly higher sensitivity of the IFN-/IL-10 ratio is due to the
fact that IL-10 levels decrease (Fig. 3) while IFN- levels
increase (Fig. 4) during treatment.
DISCUSSION
M. tuberculosis has evolved efficient ways to evade host de-
fense by down-regulating various key elements of the cell-
mediated immune system. Since we and others have reported
that immunity to mycobacteria is critically dependent on type
1 immunity, involving the IL-12/23/IFN-/IFN-R, NFB, and
TNF-/TNF-R axes (14, 31, 44), we hypothesized that im-
pairment of these pathways could be related to TB disease. We
therefore designed a study to analyze the integrity of these
pathways in active and cured TB in an area where TB is highly
endemic in order to take into account the impact of environ-
mental as well as tuberculous mycobacterial exposure on the
population’s immunity (9). We report that in this population
where TB is endemic—with high exposure to tuberculous and
nontuberculous mycobacteria—M. tuberculosis-induced IFN-
production, as well as IFN-R signaling, was significantly
down-regulated during active TB. Decreased IFN- produc-
tion had an M. tuberculosis-specific component which was re-
versible and a nonspecific component which did not seem to
normalize during treatment. Longer follow-up studies are
needed to substantiate the possible permanence of the de-
creased IFN- production in TB-susceptible individuals. Fur-
thermore, M. tuberculosis-specific (but not nonspecific) IFN-
production levels correlated inversely with TB disease severity.
IFN--inducible responses, as measured by synergy with M.
tuberculosis or LPS stimulation, were also significantly de-
pressed during active disease and normalized during treat-
ment, suggesting a disease activity-related, reversible impair-
ment in IFN-R signaling in TB. TNF- and IFN- levels
showed opposite trends, since TNF- production was higher in
active-TB patients than in controls. IL-12/23p40 production
kinetics did not correlate with disease activity, showing that the
depressed IFN- production found is not due to decreased
IL-12/IL-23 production. IFN-/IL-10 and IFN-/TNF- ratios
were found to be particularly significantly regulated biomarker
signatures that correlated strongly with TB cure, showing a
shift toward a proinflammatory cytokine profile during success-
FIG. 7. TNF-/IL-10 ratios were significantly increased in TB patients before, during, and following completion of therapy compared to those
of control subjects. By contrast, IL-12/23p40/IL-10 ratios were only temporarily increased during anti-TB therapy and decreased at the end of
therapy. The ratio of M. tuberculosis-specific IFN- to IL-10 production showed a strong increase during the course of therapy and was slightly
increased at the end of therapy compared to that of control subjects, suggesting a shift toward a proinflammatory host immune phenotype during
control of infection. Each dot represents one individual. A horizontal bar indicates the median level of each group. A dashed line indicates a ratio
of 1. A statistically significant difference (P
 0.05) is indicated by the symbol # (Wilcoxon signed-rank test) between median values before, during,
and at the end of therapy or by the symbol  (Mann-Whitney U test) compared to control subjects.
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ful treatment. Taken together, M. tuberculosis appears to be
capable of interfering in multiple key steps in innate and adap-
tive IFN--dependent immunity. The depression of both
IFN- production and IFN-R signaling may synergize in con-
tributing to defective host control of M. tuberculosis infection
in active TB.
From in vitro models, it is well known that M. tuberculosis
infection in macrophages can inhibit the induction of a subset
of IFN--responsive genes, including Fc receptor type I and
major histocompatibility complex class II transactivator (12,
36, 46). Our results clearly suggest that during active TB dis-
ease, not only M. tuberculosis-specific induced IFN- produc-
tion but also IFN-R signaling is impaired. Consequently,
there is suppression of both innate and adaptive immunity in
active TB. Human IFN- production depends on IL-12/23, and
IL-12/23 is critical for the control of tuberculous and nontu-
berculous mycobacterial infections in mice and humans (2, 3,
13). M. tuberculosis inhibits in vitro IL-12/23p40 mRNA and
protein production in human (34) and mouse (16) macro-
phages, indicating active repression of IL-12/23p40 induction
by live M. tuberculosis. One study has reported depressed IL-12
production in response to the M. tuberculosis 30/32-kDa anti-
gen in active pulmonary TB (45). In our study, however, there
was no suppression of IL-12/23p40 in active pulmonary TB
patients compared to controls. We cannot exclude the possi-
bility that in untreated patients M. tuberculosis infection masks
increased inflammatory IL-12/23p40 responses, compatible
with our observation that there was a temporary increase in
IL-12/23p40 production after 2 months of treatment. The latter
could have resulted from treatment-induced killing of M. tu-
berculosis, which would both inhibit IL-12/23p40 suppression
and drive stimulation of inflammatory responses, including
IL-12/23p40 production, by the concomitant release of M. tu-
berculosis products. Regardless of the peak in IL-12/23p40
production at 2 months, however, IFN- responses had not
normalized. The high IL-12/23p40 levels at 0 and 2 months in
the absence of high IFN- production suggest that there is
active suppression of IFN- production, which is not depen-
dent on IL-12/23p40 regulation. In previous studies, we
showed that human macrophages, when stimulated by M. tu-
berculosis, release IL-23 (p40/p19) but no IL-12p70 (p40/p35).
Only in the presence of IFN- as an accessory factor were
IL-12p35 gene transcription and IL-12p70 (p40/p35) protein
production induced (57). Thus, both IL-12 and IL-23 can be
released by human macrophages in response to M. tuberculosis
but this depends on the context of stimulation. In the present
study, we attempted to measure the production of IL-23 but
were unable to detect IL-23 protein over the assay’s back-
ground.
Furthermore, the suppression of IFN- production weakly
correlated with increased levels of IL-10 (Fig. 3). IL-10 pro-
duction has been observed in active TB (11, 50), and a recent
study suggested that the combined production of IL-10 and
TGF- might act to down-modulate pulmonary immunity to
M. tuberculosis, allowing M. tuberculosis to evade type 1 immu-
nity (10). In our study, the increase in IFN- production during
TB therapy also coincided with slightly reduced IL-10 produc-
tion, in agreement with the possibility that IL-10 and IFN-
cross-regulate. Furthermore, IL-10 down-regulates the expres-
sion of the IL-12 receptor chain in TB. Since TB patients also
have reduced levels of IL-12R expression (60), their cells may
be less responsive to IL-12, which may partly account for the
lower level of IFN- production in active TB. The latter study
also reported that anti-IL-10 and anti-TGF- enhanced IL-
12R1 and IL-12R2 expression and IFN- production.
In our study, active-TB patients had a striking depression of
IFN- production in response to specific M. tuberculosis stim-
ulation. While this has been reported before (18, 27, 29, 39, 47,
51), our comparative analysis of M. tuberculosis- versus mito-
gen-induced IFN- production suggests that there may be a
more general—acquired or inherent—impairment in maxi-
mum IFN- production capacity in TB patients—at least dur-
ing the first 6 months following the start of treatment—next to
a prominent defect which is antigen specific. It is not clear
whether IFN- production in these individuals will normalize
at later time points, and additional studies are required to
resolve this. The observation that the depression of IFN-
production following stimulation with a specific antigen (M.
tuberculosis) normalized following treatment is compatible
both with the disappearance of specific suppression and with
the recruitment of antigen-specific T cells from sequestered
lesions into the peripheral compartment (6, 7). However, the
fact that mitogen-induced responses remain significantly lower
in active-TB patients than in controls is less easily compatible
with these possibilities and might argue in favor of a more
permanent defect in IFN- production capacity. The observa-
tion that this latter difference between patients and controls
failed to become apparent following M. tuberculosis stimula-
tion may be due to the recruitment of increased numbers of
antigen-specific cells from active-TB sites into the peripheral
compartment following microbiological cure. However, these
parameters were not measured in this study, and future work
will need to determine frequencies of such responsive cells by
using quantitative assays.
There was no difference in M. tuberculosis-induced IFN-
production in patients or controls with or without BCG scars,
even though the presence of a scar was associated with pro-
tection against advanced TB. However, the absence of a BCG
scar cannot rule out possible past BCG vaccination.
In contrast to IL-12 and IFN- production, TNF- produc-
tion was increased during active TB, suggesting that proinflam-
matory cytokine production was not generally impaired in ac-
tive TB (4, 58). TNF- production normalized during curative
treatment and correlated with TB disease activity rather than
disease severity. The balance of pro- versus anti-inflammatory
cytokines is important in clinical outcome in several human
diseases. TNF-/IL-10 ratios were significantly increased in TB
patients at all time points before, during, and following com-
pletion of therapy compared to those of the control subjects
(P 
 0.05). By contrast, IL-12p40/IL-10 ratios were only tem-
porarily increased during anti-TB therapy and decreased at the
end of therapy.
The ratios of M. tuberculosis-specific IFN- production over
IL-10 and TNF- production both showed a strong increase
during the course of therapy and were slightly increased at the
end of therapy compared to those of control subjects. These
results strongly suggest a shift toward a proinflammatory host
immune phenotype during control of infection.
We did not measure IL-17 in this study. IL-17 is an impor-
tant inflammatory cytokine whose production is differentially
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regulated by IL-23 and IL-12; IL-23 promotes while IL-12
inhibits IL-17 production, even though both IL-12 and IL-23
enhance IFN- production (28). Through this anti-inflamma-
tory property, IL-12 may limit inflammation while enhancing
specific adaptive immunity by increasing T-cell IFN- produc-
tion. In mice, IL-12 can modulate pathology by reducing the
numbers of immune cells involved in inflammatory tuberculous
lesions (35). Moreover, IL-12 is also able to enhance IL-10
production, a property often not recognized (32, 54). Thus,
IL-12 likely has several different roles in host responses to
infection, including a previously unknown anti-inflammatory
role.
Collectively, our results show that M. tuberculosis-specific
stimulation of IFN- production and IFN-R signaling are
both significantly depressed in clinically active TB. Both cor-
related with TB disease severity and activity and normalized
during microbiological TB cure. We propose that the depres-
sion of both IFN- production and IFN-R signaling syner-
gizes in contributing to defective host control of M. tuberculosis
infection in active TB.
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